Linked Life Data

10804282

Source:http://linkedlifedata.com/resource/pubmed/id/10804282

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2000-6-29
pubmed:abstractText
Adenoviral (Ad) vectors are commonly used in gene therapy trials because of their efficiency in gene transfer. However, their use is limited by immune responses that reduce transgene expression and decrease the efficacy of repeated vector administration. In this study, we demonstrated that conjugation of Ad vector with our novel cationic liposomes could reduce viral antigenicity in vivo. Mice subcutaneously injected with liposome-conjugated Ad vector showed a 6.5-fold reduction of anti-Ad antibodies with neutralizing activity, compared to those with unconjugated Ad vector. Interestingly, we also found that the conjugated vector is less susceptible to inactivation by neutralizing antibodies in vitro and in vivo. Our results suggest that liposome conjugation reduces viral antigenicity, shields vectors from neutralizing antibody, and may allow repeated Ad vector administration.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0910-5050
pubmed:author
pubmed:issnType
Print
pubmed:volume
91
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
363-7
pubmed:dateRevised
2006-4-21
pubmed:meshHeading
pubmed:year
2000
pubmed:articleTitle
Cationic liposome conjugation to recombinant adenoviral vector reduces viral antigenicity.
pubmed:affiliation
Department of Neurosurgery, Nagoya University School of Medicine, 65 Tsuruimai-cho, Showa-ku, Nagoya 466-8550, Japan.
pubmed:publicationType
Journal Article